These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 23379025)

  • 21. [Lithium carbonate in Huntington's disease].
    Vardi J; Flechter S; Alelov M; Rabey Y; Streifler M
    Harefuah; 1978 Mar; 94(5-6):168-70. PubMed ID: 149052
    [No Abstract]   [Full Text] [Related]  

  • 22. Penicillamine in Huntington's chorea.
    Bird ED; Pilling JB; Heathfield KW
    Postgrad Med J; 1974 Aug; 50 Suppl 2():24-6. PubMed ID: 4282872
    [No Abstract]   [Full Text] [Related]  

  • 23. [Value of lithium salts in the treatment of Huntington's chorea].
    Tridon P; Arnould G; Barroche M
    Nouv Presse Med; 1977 Aug 27-Sep 3; 6(28):2523-4. PubMed ID: 144267
    [No Abstract]   [Full Text] [Related]  

  • 24. Tetrabenazine (Xenazine) for Huntington's chorea.
    Med Lett Drugs Ther; 2009 Jan; 51(1304):7-8. PubMed ID: 19172140
    [No Abstract]   [Full Text] [Related]  

  • 25. Medical marijuana in Huntington's disease: report of two cases.
    Meisel K; Friedman JH
    Med Health R I; 2012 Jun; 95(6):178-9. PubMed ID: 22866505
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of Huntington's chorea with isoniazid.
    Perry TL; MacLeod PM; Hansen S
    N Engl J Med; 1977 Oct; 297(15):840. PubMed ID: 142923
    [No Abstract]   [Full Text] [Related]  

  • 27. Steroid therapy in Huntington's disease.
    Bonuccelli U; Nuti A; Maremmani C; Ceravolo R; Muratorio A
    Adv Biochem Psychopharmacol; 1992; 47():149-54. PubMed ID: 1387281
    [No Abstract]   [Full Text] [Related]  

  • 28. Isoniazid and Huntington's chorea.
    Roccatagliata G; Albano C
    N Engl J Med; 1978 Feb; 298(8):457. PubMed ID: 146161
    [No Abstract]   [Full Text] [Related]  

  • 29. Kainic acid animal model predicts therapeutic agents in Huntington's chorea.
    Borison RL; Diamond BI
    Trans Am Neurol Assoc; 1979; 104():67-9. PubMed ID: 162258
    [No Abstract]   [Full Text] [Related]  

  • 30. Drug holiday in Huntington's disease.
    Schmidt EZ; Hofmann P; Kapfhammer HP; Bonelli RM
    Ann Pharmacother; 2005 Apr; 39(4):773. PubMed ID: 15741414
    [No Abstract]   [Full Text] [Related]  

  • 31. Huntington's disease: clinical effects of a short-term treatment with pimozide.
    Arena R; Iudice A; Virgili P; Moretti P; Menchetti G
    Adv Biochem Psychopharmacol; 1980; 24():573-5. PubMed ID: 6447434
    [No Abstract]   [Full Text] [Related]  

  • 32. Reserpine action in Huntington's chorea.
    Calabrese VP
    N Engl J Med; 1973 Jul; 289(2):104. PubMed ID: 4267988
    [No Abstract]   [Full Text] [Related]  

  • 33. Amantadine in Huntington's chorea.
    Weiner WJ; Klawans HL
    N Engl J Med; 1972 Jan; 286(2):106. PubMed ID: 4256208
    [No Abstract]   [Full Text] [Related]  

  • 34. Putting the Brakes on Huntington Disease in a Mouse Experimental Model.
    Kim JC; Mirkin SM
    PLoS Genet; 2015 Aug; 11(8):e1005409. PubMed ID: 26247607
    [No Abstract]   [Full Text] [Related]  

  • 35. Clozapine in Huntington's disease.
    Colosimo C; Cassetta E; Bentivoglio AR; Albanese A
    Neurology; 1995 May; 45(5):1023-4. PubMed ID: 7746380
    [No Abstract]   [Full Text] [Related]  

  • 36. Laquinimod, Huntington's disease, and disease modification.
    Mestre TA
    Lancet Neurol; 2024 Mar; 23(3):220-221. PubMed ID: 38280390
    [No Abstract]   [Full Text] [Related]  

  • 37. Game-changer in the fight against Huntington's disease: Cholesterol nanoparticles restore brain function in mice.
    Martín MG; Dotti CG
    Pharmacol Res; 2023 Aug; 194():106879. PubMed ID: 37536639
    [No Abstract]   [Full Text] [Related]  

  • 38. Promising compound targets mitochondria in Huntington's disease.
    Parks L
    Future Med Chem; 2013 Jan; 5(1):18. PubMed ID: 23379025
    [No Abstract]   [Full Text] [Related]  

  • 39. 4-hydroxy tempo improves mitochondrial and neurobehavioral deficits in experimental model of Huntington's disease.
    Sandhir R; Mahajan N; Mehrotra A; Aggarwal A; Sunkaria A
    Synapse; 2015 Mar; 69(3):128-38. PubMed ID: 25482019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting of XJB-5-131 to mitochondria suppresses oxidative DNA damage and motor decline in a mouse model of Huntington's disease.
    Xun Z; Rivera-Sánchez S; Ayala-Peña S; Lim J; Budworth H; Skoda EM; Robbins PD; Niedernhofer LJ; Wipf P; McMurray CT
    Cell Rep; 2012 Nov; 2(5):1137-42. PubMed ID: 23122961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.